BridgeBio Pharma, Inc. — Director's Dealing 2020

Dec 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-12-28

Reporting Person: Turtle Cameron (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-28	Common Stock	M	7500	$17.00	Acquired	20068	Direct
2020-12-28	Common Stock	M	6000	$0.34	Acquired	26068	Direct
2020-12-28	Common Stock	M	6000	$0.16	Acquired	32068	Direct
2020-12-28	Common Stock	S	10937	$69.3361	Disposed	21131	Direct
2020-12-28	Common Stock	S	8563	$69.9352	Disposed	12568	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-28	Stock Option (Right to Buy)	$17.00	M	7500	Disposed	2029-06-26	Common Stock (7500)	Direct
2020-12-28	Stock Option (Right to Buy)	$0.34	M	6000	Disposed	2029-07-14	Common Stock (6000)	Direct
2020-12-28	Stock Option (Right to Buy)	$0.16	M	6000	Disposed	2029-05-23	Common Stock (6000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020.

F2: Represents the weighted average sale price of the shares sold from $68.73 to $69.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: Represents the weighted average sale price of the shares sold from $69.73 to $70.52 per share.

F4: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.